Glycemic control and oxidative stress with glimepiride or nateglinide alone in type 2 OHA [oral hypoglycaemic agent]-naive diabetic patients.
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 12 May 2016
At a glance
- Drugs Glimepiride (Primary) ; Nateglinide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 04 Apr 2011 Planned end date (Mar 2008) added as reported by University Hospital Medical Information Network - Japan.
- 04 Apr 2011 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 31 May 2007 New trial record.